UroGen Pharma Ltd.

URGNNASDAQHealthcareBiotechnology

$34.04- (-)1Y +102.83%

As of Oct 26, 2026 close

Market cap: $1.71B
P/E (TTM): -
Forward P/E: -
Dividend yield: -
52-week range: $16.50$50.81
Volume (live): -
Avg. volume (3M): 930.84K

UroGen Pharma Ltd. (URGN) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for UroGen Pharma Ltd. stock.

Analyst Consensus Rating

Investment consensus from 7 professional research analysts

Consensus Rating

Buy

Based on 7 unique analysts

(10 total ratings in last 90 days)

Medium Confidence∞:1 Buy/Sell

Average Price Target

$60.20

+76.85% upside

Loading chart...

Strong Sell

Sell

Hold

Buy

Strong Buy

Latest URGN Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Date	Analyst	Firm	Action	Rating	Price Target
Oct 20, 2026	Michael Schmidt	Guggenheim	Maintains	Buy	$58.00
Oct 19, 2026	Ram Selvaraju	HC Wainwright	Reiterates	Buy	$75.00
Oct 13, 2026	Bret Jensen	TheStreet.com	Initiates Coverage	Buy	-
Aug 21, 2026	Zacks Equity Research	Zacks Equity Research	Initiates Coverage	Buy	-
Aug 20, 2026	Ram Selvaraju	HC Wainwright	Reiterates	Buy	$75.00
Aug 6, 2026	Michael Schmidt	Guggenheim	Maintains	Buy	$42.00 → $58.00 +16.00 (+38.1%)
Aug 6, 2026	Paul Choi	Goldman Sachs	Maintains	Hold	$44.00 → $48.00 +4.00 (+9.1%)
Aug 6, 2026	Leland Gershell	Oppenheimer	Reiterates	Buy	$50.00 → $60.00 +10.00 (+20.0%)
Aug 5, 2026	Tara Bancroft	TD Cowen	Reiterates	Buy	$50.00 → $60.00 +10.00 (+20.0%)
Aug 5, 2026	Paul Choi	Goldman Sachs	Maintains	Hold	$44.00 → $48.00 +4.00 (+9.1%)

Michael Schmidt

Guggenheim

BuyMaintains

$58.00

Oct 20

Ram Selvaraju

HC Wainwright

BuyReiterates

$75.00

Oct 19

Bret Jensen

TheStreet.com

BuyInitiates Coverage

Oct 13

Zacks Equity Research

BuyInitiates Coverage

Aug 21

Ram Selvaraju

HC Wainwright

BuyReiterates

$75.00

Aug 20

Michael Schmidt

Guggenheim

BuyMaintains

$42.00 → $58.00

Aug 6

Paul Choi

Goldman Sachs

HoldMaintains

$44.00 → $48.00

Aug 6

Leland Gershell

Oppenheimer

BuyReiterates

$50.00 → $60.00

Aug 6

Tara Bancroft

TD Cowen

BuyReiterates

$50.00 → $60.00

Aug 5

Paul Choi

Goldman Sachs

HoldMaintains

$44.00 → $48.00

Aug 5

Source: Professional analyst ratings and price targets from the last 90 days. Data as of Oct 20, 2026. Data sources and methodology

Frequently Asked Questions

What is the analyst consensus rating for URGN?

The analyst consensus rating for URGN is Buy, based on the latest ratings from 7 analysts over the last 90 days.

What is the average price target for URGN?

The average 12-month price target for URGN is $60.20, representing an upside of 76.9% from the Oct 26, 2026 close of $34.04.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.